Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice

Nonalcoholic steatohepatitis (NASH) is a rapidly developing pathology around the world, with limited treatment options available. Some farnesoid X receptor (FXR) agonists have been applied in clinical trials for NASH, but side effects such as pruritus and low‐density lipoprotein elevation have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jie, Ma, Yuandi, Liu, Yameng, Lu, Dasheng, Gao, Xiaoxia, Krausz, Kristopher W., Desai, Dhimant, Amin, Shantu G., Patterson, Andrew D., Gonzalez, Frank J., Xie, Cen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701488/
https://www.ncbi.nlm.nih.gov/pubmed/36196594
http://dx.doi.org/10.1002/hep4.2099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701488/
https://www.ncbi.nlm.nih.gov/pubmed/36196594
http://dx.doi.org/10.1002/hep4.2099

Ejemplares similares